Similar articles

• Aetiology and resistance patterns of community-acquired pneumonia in León, Nicaragua.

  Matute AJ, Brouwer WP, Hak E, Delgado E, Alonso E, Hoepelman IM. Matute AJ, et al. Int J Antimicrob Agents. 2006 Nov;28(5):423-7. doi: 10.1016/j.ijantimicag.2006.07.016. Epub 2006 Oct 12. Int J Antimicrob Agents. 2006. PMID: 17046211
• Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections.

  Nicolau DP. Nicolau DP. Am J Manag Care. 2004 Oct;10(12 Suppl):S381-8. Am J Manag Care. 2004. PMID: 15603247 Review. No abstract available.
• Adult community-acquired pneumonia caused by macrolide resistant Mycoplasma pneumoniae.

  Isozumi R, Yoshimine H, Morozumi M, Ubukata K, Ariyoshi K. Isozumi R, et al. Respirology. 2009 Nov;14(8):1206-8. doi: 10.1111/j.1440-1843.2009.01619.x. Epub 2009 Sep 1. Respirology. 2009. PMID: 19732389
• Chlamydia pneumoniae and Mycoplasma pneumoniae.

  Blasi F, Tarsia P, Aliberti S, Cosentini R, Allegra L. Blasi F, et al. Semin Respir Crit Care Med. 2005 Dec;26(6):617-24. doi: 10.1055/s-2005-925525. Semin Respir Crit Care Med. 2005. PMID: 16388430 Review.
• C-reactive protein for discriminating treatment failure from slow responding pneumonia.

  Ruiz-González A, Falguera M, Porcel JM, Martínez-Alonso M, Cabezas P, Geijo P, Boixeda R, Dueñas C, Armengou A, Capdevila JA, Serrano R. Ruiz-González A, et al. Eur J Intern Med. 2010 Dec;21(6):548-52. doi: 10.1016/j.ejim.2010.09.006. Eur J Intern Med. 2010. PMID: 21111942